A B S T R A C T

Background
Vitamin C is one of the key antioxidant vitamins which is abundant in the extracellular fluid lining the lung and low vitamin C intake has been associated with pulmonary dysfunction.
Objectives
To evaluate the evidence for the efficacy of vitamin C in the treatment of asthma.
Search methods
The Cochrane Airways Review Group asthma register was searched and bibliographies of studies identified were also checked for further trials. This review has been updated by searches to August 2008.
Selection criteria
Only randomised controlled trials were eligible for inclusion. Studies were considered for inclusion if they dealt with the treatment of asthma using vitamin C supplementation. Two independent reviewers identified potentially relevant studies using pre-defined criteria and selected studies for inclusion.
Data collection and analysis
Data were abstracted independently by two reviewers. Information on patients, methods, interventions, outcomes and results was extracted using standard forms.
Main results
Nine studies met the review entry criteria, randomising a total of 330 participants. Study design varied and the reporting was generally poor. Five trials contributed numerical data to the review. They provided outcome data on lung function, symptom scores, IgE levels and inhaled steroid use. One small study showed a significant difference in % drop in FEV1 post-exercise.
At present, evidence from randomised-controlled trials is insufficient to recommend a specific role for vitamin C in the treatment of asthma. Further methodologically strong and large-scale randomised controlled trials are needed in order to address the question of the effectiveness of vitamin C in asthma.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C supplementation for asthma
Asthma is a chronic inflammatory disease of the airways characterised by wheeze and breathlessness. One theory for the observed increase in the number of people with asthma is the 'western' diet with it's lack of nutrients from fresh food. We reviewed evidence from nine trials of the antioxidant vitamin C as a treatment for asthma. In general the trials were small, varied greatly in their design and the reporting was poor. From the available evidence it is not possible to recommend either the use or avoidance of vitamin C supplements in asthma.
B A C K G R O U N D
Asthma is now recognised as a chronic inflammatory disease resulting in reversible airways bronchoconstriction (Holgate 1990) . The incidence and prevalence of asthma has increased in many countries over the past few decades. The most marked increase has been observed in children (Strachan 1999; Lewis 1996) . This may be due to changing environmental exposures or the increased susceptibility of populations with reduced host resistance (Seaton 1994).
One hypothesised cause for this increase is that changes in "western" diet have produced a reduction in host resistance over time. In particular recent interest has focused on the association between anti-oxidants in diets and health outcomes. Cross-sectional studies show that infrequent fruit consumption is associated with reduced lung function, both in children (Cook 1997) and adults (Butland 1999) . In addition, the National Food Survey has documented a drop in the consumption of antioxidant food sources such as fresh fruit and vegetables in countries such as Great Britain since the 1950's (Seaton 1994).
Vitamin C is one of the key antioxidant vitamins which is abundant in the extracellular fluid lining the lung. Low vitamin C intake is associated with pulmonary dysfunction (Schwartz 1994) . Both adults (Olusi 1979) and children (Aderele 1985) with asthma have been found to have lower concentrations of vitamin C when compared to normal subjects. Patients with asthma may have low supplies of vitamin C or an increased demand for vitamin C in the face of an oxidant load resulting in depletion. There is a need to clarify whether supplementation with vitamin C may bring benefits in reducing morbidity, improving pulmonary function or quality of life in patients with asthma.
There have been three recent reviews of the literature on the role of vitamin C in asthma (Bielory 1994; Hatch 1995; Monteleone 1997) . However, the review by Bielory et al (Bielory 1994) only searched the English language literature using MEDLINE and gave no further details as to how the studies had been located. The other two reviews did not specify their methodology. These reviews reached different conclusions. Bielory et al (Bielory 1994) concluded that the role of vitamin C in asthma was unclear and that current literature did not support its use. The review by Hatch et al (Hatch 1995) found 7 out of 11 studies indicated that vitamin C supplementation might reverse or improve asthma symptoms. The review by Monteleone et al (Monteleone 1997) offers the opinion that vitamin C provides a short term protective effect on airway responsiveness, but less clear impact on other objective lung function measurements. All three reviews recommend further studies into the role of vitamin C in asthma. As a first step, a review using the Cochrane methodology is needed to systematically weigh the quality of the existing evidence before recommending any future studies.
O B J E C T I V E S
To determine the overall efficacy of vitamin C supplementation in patients with stable chronic asthma.
Criteria for considering studies for this review
Types of studies
To be eligible, all studies needed to be randomised-controlled trials (RCTs). Double-blinded trials were preferred, but single blind and open studies were also reviewed for possible inclusion.
Types of participants
Studies were considered for inclusion if they recruited adults and/ or children with chronic stable asthma, seasonal asthma or those with exercise-induced bronchospasm. Studies of other allergic conditions such as hay fever, allergic rhinitis and eczema were only considered if the results for subjects with asthma were presented separately. Vitamin C studies, which reported outcomes on patients with asthma separately as a sub-group, were also considered for inclusion.
Types of interventions
Vitamin C supplementation compared to placebo or "standard care". We considered studies that administered vitamin C via any route, dosage or dose interval. Both single dose and longer -term studies were considered for inclusion.
Types of outcome measures
Primary outcome measures 1) Lung function (e.g. FEV1, PEFR) 2) Symptoms (e.g. symptom scores)
Secondary outcome measures
3) Functional outcomes (e.g. quality of life, sickness absence, exercise capacity) 4) Non-specific bronchial hyper-reactivity (BHR) to histamine or methacholine 5) Immunological markers (IgE levels) 6) Asthma medication requirements (e.g. additional steroid or bronchodilator usage) 7) Health service utilisation (e.g. GP attendance, hospital admissions) 8) Asthma exacerbations
Search methods for identification of studies Electronic Searches
Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see the Airways Group Module for further details). All records in the Specialised Register coded as 'asthma' were searched using the following terms: ascorbic* or "vitamin c" or antioxid* The most recent search was conducted in August 2008.
Other sources
Reference lists of all primary studies and review articles were reviewed for additional references. Authors of identified trials were contacted.
Data collection and analysis
Retrieval of studies
All trials that appeared potentially relevant were assessed by two independent reviewers for relevance using abstract and title from the electronic search. Using texts from all potentially relevant articles, final inclusion was also determined independently by two reviewers. Disagreements about study inclusion were resolved with discussion.
Assessment of methodological quality
The quality of included studies was assessed using the Cochrane approach. A risk of bias table was completed for each study assessing the reporting of method of randomisation, allocation concealment and blinding. Each item was judged as being adequate, unclear or inadequate. Any disagreements between reviewers were resolved by discussion.
Data abstraction
Data were extracted independently by two reviewers and entered in the Cochrane Collaboration Software, Review Manager (RevMan). For studies where the original data were not presented, when possible, they were extracted from graphically representations. Study outcomes that were reported post-bronchial challenge (e.g. exercise or histamine) were analysed separately from outcomes that did not involve bronchial challenge or when results were reported before such challenges (but post-dose vitamin C administration).
Statistical considerations
Outcomes from included trials were combined using RevMan. For continuous outcomes the weighted mean difference (WMD) with fixed effect was used to estimate the individual effect sizes and 95% confidence intervals (95% CI). If there were any dichotomous outcomes the Peto fixed or random effect model was to be used to estimate the pooled odds ratio (OR) and 95% CI. The main planned comparison for statistical consideration was any form or dose of vitamin C supplementation versus placebo or "standard care". If there were adequate included studies, the following pre-defined sub-group analysis were planned: 1. Single dose versus chronic administration of vitamin C 2. Dietary advice to increase vitamin C consumption versus no intervention 3. Oral vitamin C versus intravenous vitamin C supplementation 4. Adults versus children 5. Males versus females
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. Details of the search history and results can be found in Table  1 . For the 2008 update, 39 new references were identified and the full text of 15 of these were retrieved. One additional included study (Tecklenburg 2007) , an extension to a previously included study (Fogarty 2003) , and 5 further excluded studies were identified. The review now contains a total of nine studies which meet the inclusion criteria. Further details can be found in the table, "Characteristics of included studies". A total of twelve studies were excluded after examining the full-text paper. Please see "Characteristics of excluded studies" for further details. The included studies were conducted in the USA (Kordansky 1979; Schachter 1982 ,Tecklenburg 2007 , Nigeria (Anah 1980) , South Africa (Anderson 1983), Canada (Malo 1986), Israel (Cohen 1997) and the UK (Fogarty 2003; O'Sullivan 2000) . Three studies examined the impact of vitamin C supplementation on exercise challenge tests in subjects with a confirmed diagnosis of exercise-induced asthma (Cohen 1997; Schachter 1982 , Tecklenburg 2007 . Two studies examined the impact of vitamin C administration on bronchial hyper responsiveness to histamine challenge tests in participants with asthma (Malo 1986; O'Sullivan 2000) . Four studies examined the impact of vitamin C on bronchial hyper responsiveness to allergen challenge in subjects sensitive to ragweed allergen (Kordansky 1979) , frequency of asthma exacerbations due to infection (Anah 1980) , lung function and immunological markers in patients with asthma (Anderson 1983) and clinical control of asthma in primary care (Fogarty 2003) . Three of the studies (Anah 1980; Anderson 1983; Fogarty 2003) followed a parallel study design and the remaining 6 used crossover designs. Data from the two types of study designs were presented separately in RevMan. No usable data could be extracted from the reports of four studies (Anah 1980; Kordansky 1979; Malo 1986; O'Sullivan 2000) , despite attempts at author contact. Seven studies (Anah 1980; Fogarty 2003; Kordansky 1979; Malo 1986; O'Sullivan 2000; Schachter 1982 , Tecklenburg 2007 reported a washout period. It has been suggested that after a single oral dose of vitamin C, at least 1-2 days is required for excretion depending on pre-existing body levels (Bates 2001). Included studies reported disparate outcome measures, which made aggregation for the purpose of a meta-analysis difficult. Most of the studies did not report the actual data in the published papers or did not provide sufficient data for a meta-analysis, although attempts were made to contact the authors for data. Outcome measures included a variety of lung function tests, symptoms and symptom scores, immune markers and reduction in the use of inhaled steroids.
Risk of bias in included studies
In general, the reporting quality of the studies was poor. All the included studies were reported as being randomised, however, only one study (Fogarty 2003) reported the method of randomisation and just three of the nine studies reported the method of allocation concealment (Anah 1980 , Fogarty 2003 , Malo 1986 . Four studies reported the method of blinding (Anah 1980 , Malo 1986 , Schachter 1982 , Tecklenburg 2007 , while one study was inadequately blinded (Anderson 1983 ) and the remaining four were unclear. None of the studies adequately reported all three methods of randomisation, allocation concealment or blinding. Anah 1980 , Fogarty 2003 and Malo 1986 gave the most detailed account. An overview of our judgments of are presented in Figure 1 and Figure  2 . 
Effects of interventions
Of the nine included studies, five have contributed numerical data to the review: Anderson 1983 , Cohen 1997 , Fogarty 2003 , Schachter 1982 and Tecklenburg 2007 . Four studies (Anah 1980; Kordansky 1979; Malo 1986 ; O'Sullivan 2000) did not report data in an manner that permitted further analysis and author contact has been unsuccessful. However, none of these studies found a significant difference for the effect of vitamin C on lung function or symptoms. Studies could not be combined statistically, because those which addressed similar comparisons used different interventions or outcome variables. For example, there were three studies where the protective effects of vitamin C were investigated using exercise challenge. All three reported pulmonary function outcomes, but Cohen 1997 only reported results from 11 of the 20 randomised participants (who were found to have a fall in FEV1 of less than 15% following vitamin C), Schachter 1982 reported absolute change post-exercise and Tecklenburg 2007 was a two week intervention study rather a single dose study, and reported maximum percentage fall from baseline.
Primary outcomes Lung function
Single dose studies Change in FEV1 (L) -post-exercise challenge: (MD 0.13; 95% CI -0.05 to 0.31) (, Schachter 1982) . Cohen reported that 11 of the 20 participants had a change of FEV1 after exercise of less than 15% following vitamin C but all 20 participants had a change of 15% or more following placebo. Mean changes were only presented for the 11 participants who had better results with vitamin C, and these are not included as this is a biased estimate of the true expected treatment effect. There were no data from any of the included studies for health service utilisation. Data on acute exacerbations was provided by one study (Anah 1980) . There were nine exacerbations in the intervention group which had 22 patients and 35 exacerbations in the placebo group which had 19 patients. Thus some patients had more than one exacerbation. Data concerning the number of patients who had one or more exacerbations would be more meaningful since it would not be subjected to bias from a few patients with recurrent exacerbations.
Adverse effects
Only one study (Anah 1980) reported on adverse effects. None of the participants in either group experienced any side effects.
D I S C U S S I O N
We found nine randomised controlled trials assessing vitamin C supplementation as a treatment for asthma. These covered singledose, short-term and long-term administration. Because the studies were very diverse and reported outcomes in different ways, it was not possible to pool the results. Four of the studies did not contribute any numerical data to the review, although none of these reported a significant difference for either of our primary outcomes of lung function and symptom scores. The only outcome reported by more than one study was pre-exercise FEV1, but the results from the different studies were not suitable for pooling in a meta-analysis.
One study (Tecklenburg 2007) found a significant difference in favour of vitamin C on the percentage drop in FEV1 post-exercise in mild-to-moderate persistent asthmatics with exercise-induced asthma. This was a small study of eight participants who were assigned to vitamin C or placebo for two weeks, then crossed over after a one week washout period. The size and duration of the trial means that the positive outcome should be interpreted with caution.
The reporting of the trial methods was generally poor. The method of randomisation, allocation concealment and blinding was not always clear, leaving the results open to bias. Only one study reported on adverse effects. No side effects were experienced by any participant in the vitamin C or placebo group, and Vitamin C is generally considered to be safe in recommended amounts, however, mega-doses can cause adverse effects (MedlinePlus 2008) so it is still important for adverse effects to be documented in trial reports.
Previous reviews of vitamin C in asthma (Bielory 1994 , Hatch 1995 , Monteleone 1997 all recommended more research before any solid conclusions can be drawn. Although all but one of the studies included in this review appear to show no effect of vitamin C on asthma, the diversity of the study designs meant that it was not possible to combine them to gain an overall picture. The role of vitamin C in asthma is still unclear.
A U T H O R S ' C O N C L U S I O N S Implications for practice
At present, evidence from the limited number of randomisedcontrolled trials is insufficient to recommend a specific role for vitamin C in the treatment or management of asthma.
Implications for research
Further randomised, double blind, placebo controlled trials of vitamin C supplementation in asthma are needed, particularly in children. When designing such a trial, attention must be paid to well defined interventions excluding known confounders (e.g., smoking, caffeine, drugs), statistical power (to show clinically relevant differences) and the relevance of outcomes (e.g., lung function, symptoms, medication usage, quality of life, exacerbations). It is also important to consider the pharmacokinetics / pharmacodynamics of vitamin C for adequate dosing and washout period especially when using a crossover design.
A C K N O W L E D G E M E N T S
The authors would like to acknowledge the work of Dr Felix Ram in producing the original version, and the 2004 update of this review.
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Anah 1980
Methods Randomised double-blind, placebo controlled, parallel trial. 
Cohen 1997
Methods Randomised double blind placebo controlled crossover study.
Participants 20 patients (adults & children) with diagnosed exercise-induced asthma with a fall in FEV1 >15% after exercise test on a motorised treadmill (13M;7F). Age ranging from 7-28 yrs with mean 13.8 yrs Interventions 2g of oral ascorbic acid or placebo 1 hour before a 7-minute exercise session on a treadmill. Pulmonary function tests were performed after an 8-minute rest. Procedure repeated 1 week later, with each subject receiving the alternative medication. 5 patients continued on a 2 week treatment but not able to use data as there was no control or placebo arm for this group of patients were selected as they showed protective effect with vitamin C in the 1 hour study (not randomised) 
A D D I T I O N A L T A B L E S
Search dates Results
January 2001
Thirty-five abstracts were identified from the search of the Cochrane Airways Group register, of which 6 met the inclusion criteria (Anah 1980 , Anderson 1983 , Cohen 1997 , Kordanksy 1979 , Malo 1986 , Schachter 1987 ) and 5 were added as excluded studies Schachter 1982 carried out a trial with participants who had exercise-induced bronchoconstriction (EIB) so that each of the 12 participants was administered placebo and vitamin C at different times. Thus, each participant served as his or her own control (crossover). In Table III Schachter reported pre-post-exercise change of FEV1, so that the later FEV1 was measured 5 minutes after the exercise. Because two observations are measured from the same participant, the placebo period and vitamin C period difference in FEV1 change should be analysed using the paired t-test. The FEV1 data in Schachter's Table III gives the mean difference between the vitamin C and placebo periods as 0.20 (SD 0.33) litres/s. Schachter 1982 calculated t = 2.13 in their paper, corresponding to P[1-tail] = 0.028. The review presents Schachter's FEV1 changes in Analysis 1.2. However, data in Analysis 1.2 were extracted from Schachter's Table II , which presents post-exercise FEV1 value measured immediately after the exercise. In EIB the fall in FEV1 occurs 5 to 20 minutes after the end of exercise (Rundell 2009), and even Schachter reported that, on the screening day, there was no fall in FEV1 immediately after exercise, but a significant fall 5 minutes after the exercise (Schachter 1982 Fig. 2) . Therefore, extracting the FEV1 changes from Schachter's Table II (FEV1 immediately after the exercise) is not reasonable if the purpose is to examine the effect of vitamin C on EIB. Cohen 1997 carried out an EIB trial with 20 participants who were administered placebo and vitamin C at different times (crossover). Post-exercise FEV1 was measured 8 minutes after the end of the exercise. The observations are paired also in this case and the results should be analysed using a paired test. 9 participants had FEV1 decrease >15% on both vitamin C and placebo treatments. 11 participants had >15% FEV1 decrease on placebo but <15% FEV1 decrease on vitamin C (Cohen 1997 Fig. 2) . None of the participants had the opposite effect: <15% FEV1 decrease on placebo and >15% FEV1 decrease on vitamin C. In the paired 2x2 table analysis, the question is whether the difference between the corners (here 11 and 0) is statistically significant. This difference gives z = (11-0)/sqrt(11+0) = 3.31, corresponding to P[1-tail] = 0.0005. A basic principle in controlled trial analysis requires that all randomised participants should be included in the analysis (the ITT principle). However, the review does not give the results for all of Cohen's 20 participants (Cohen 1997 Fig. 2) ; Analysis 1.2 gives the results for only the 11 participants who had benefit of vitamin C (Cohen 1997 Table 2 ). Furthermore, the review presents the average of post-exercise FEV1 values and not the pre-post-exercise difference in FEV1 in analysis 1.2. The post-exercise averages for Cohen's Table 2 are 1.66 (SD 0.80) litres/s in the placebo period and 1.93 (SD 0.78) litres/s in the vitamin C period (P = 0.42). However, given that the EIB is defined by the pre-post change in FEV1, the measurement of the effect on EIB should be based on the pre-post-exercise difference in FEV1 (Rundell 2009). Furthermore, the relative effect calculated by Cohen (Table 2 ; in %units) is a better measure than the absolute value (in litres/s) because the relative effect adjusts for the great variation in baseline FEV1; the relative decrease in FEV1 is also used in guidelines (Rundell 2009). Cohen reports that the average relative fall in FEV1 is 25% in the placebo period and 5% in the vitamin C period (Cohen 1997 table 2). Because the observations are paired, the paired t-test should be used. The average of the differences is 20% (SD 12%, SE 3.7%), which gives t = 5.57, corresponding to P[1-tail] = 0.00012. Thus, although the review presented only the 11 participants in which vitamin C was beneficial, the calculation suggests that even in this subgroup vitamin C was without effect (P = 0.42), whereas a correct calculation gives a much smaller P-value.
In their EIB trial, Tecklenburg 2007 studied 8 participants who were administered vitamin C and placebo at different times. They measured post-exercise FEV1 at 1, 5, 10, 15, 20, and 30 min after the exercise. Tecklenburg 2007 reported that the decrease in FEV1 in the vitamin C period was 6.4% (SE 2.4%) and decrease in the placebo period was 12.9% (SE 2.4%). Tecklenburg did not publish the paired comparison, nor original data so that the paired t-test could be calculated. Nevertheless, these averages give unpaired t = 1.91, corresponding to P[1-tail] = 0.038, which is conservative, the paired test P-value would be smaller. Thus, three trials included in the review found benefit of vitamin C supplementation against EIB at 5 and 8 minutes after the exercise (Cohen 1997; Schachter 1982) , or at the time of maximum fall in FEV1 (Tecklenburg 2007). The three P-values calculated above (0.028, 0.0005, 0.038) can be combined by using the Fisher method (Fisher 1948) . The combined P[1-tail] = 0.00007 provides evidence that the effects of vitamin C on EIB in these three trials are not explained by random fluctuations. Analyses 1.1, 1.3 and 1.5 present baseline data of two EIB trials discussed above (Cohen 1997; Schachter 1982) . However, when a trial specifically examines the effect of vitamin C on EIB, the relevant outcome is the difference between the baseline and the 5-10 minutes post-exercise FEV1 values (the pre-post change), and not the baseline FEV1 value alone. We thank Dr Hemilä for the feedback, but do not think that the technical issues raised over the analysis of data from the three small cross-over trials (including a total of 40 participants), substantively alter the strength or direction of the results, the quality of the evidence, or the conclusions of the review. We agree that crossover trials are best analysed using paired t-tests, but do not agree with the presentation of one-tail P values above. A two-tailed paired t-test did not show a statistically significant difference in change in FEV1 either immediately after exercise (shown in analysis 1.2) or five minutes later in Schachter 1982 (P = 0.18 and 0.057 from Table II and Table III respectively) . Therefore the author's choice not to include the latter observation does not mislead the reader in our opinion. We agree that the mean differences in FEV1 reported from only 11 of the 20 participants in Cohen 1997 should not be included in the review, and this has been removed from the analyses. 
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